PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer

Cancer statistics, 2014

Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Janis M. Taube, Alison Klein, Julie R. Brahmer et al. · Clinical Cancer Research · 2014 · 2.3K citations · Full text

Medicine, Immunology, Oncology +17

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis

Madison Black, Ivraym B. Barsoum, Peter Truesdell et al. · Oncotarget · 2016 · 184 citations · Full text

Medicine, Immunology, Oncology +17

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Marlon C. Rebelatto, Anita Midha, Amita Mistry et al. · Diagnostic Pathology · 2016 · 179 citations · Full text

Medicine, Oncology, Cancer Immunology +16

Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication

Omar A. Ali, Sarah A. Lewin, Glenn Dranoff et al. · Cancer Immunology Research · 2016 · 145 citations

Medicine, Immunology, Oncology +17